A mutant BRAF V600E-specific immunohistochemical assay: correlation with molecular mutation status and clinical outcome in colorectal cancer.

The B-type Raf kinase (BRAF) V600E mutation is a well-established biomarker for poor prognosis in metastatic colorectal cancer (mCRC) and is a highly attractive drug target. A barrier to the development of new therapies targeting BRAF V600E in mCRC is the low prevalence of mutations (approximately 1...

Descripción completa

Detalles Bibliográficos

Publicado en:	Targeted Oncology Vol. 10; no. 1; pp. 99 - 110
Autores principales:	Day, Fiona, Muranyi, Andrea, Singh, Shalini, Shanmugam, Kandavel, Williams, David, Byrne, David, Pham, Kym, Palmieri, Michelle, Tie, Jeanne, Grogan, Thomas, Gibbs, Peter, Sieber, Oliver, Waring, Paul, Desai, Jayesh
Formato:	research Journal Article
Publicado:	Springer Nature Mar2015
Acceso en línea:	Ver este registro en EBSCOhost